We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA LETS GENERICS DELETE USE LISTING ON SKELAXIN LABELING
FDA LETS GENERICS DELETE USE LISTING ON SKELAXIN LABELING
March 12, 2004
The FDA has cleared a roadblock to generic competition against King Pharmaceuticals’ muscle relaxant Skelaxin (metaxalone) by not requiring generic firms to list some prescribing information on the label.